USFDA approval granted for generic Doxycycline for Injection

This USFDA approval allows Lupin to market a generic equivalent of Vibramycin for injection, 100 mg/vial, originally developed by Pfizer Inc.

220
USFDA Approval
USFDA Approval

Last Updated on October 6, 2024 by The Health Master

USFDA approval

Lupin Limited has garnered USFDA approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for doxycycline for injection USP, 100 mg/vial (single-dose vial).

This USFDA approval allows Lupin to market a generic equivalent of Vibramycin for injection, 100 mg/vial, originally developed by Pfizer Inc.

Understanding Doxycycline for Injection USP

What is Doxycycline for Injection USP?

Doxycycline for injection USP is a crucial medication indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline and other antibacterial drugs.

It is specifically intended for intravenous administration.

Purpose of Doxycycline for Injection USP

The primary purpose of doxycycline for injection USP is to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Its formulation and dosage are tailored to ensure optimal efficacy in combating bacterial infections.

Lupin’s Manufacturing and Distribution

Production Facility

Lupin will manufacture the generic equivalent of Vibramycin for injection at its state-of-the-art facility located in Nagpur, India.

This facility adheres to stringent quality standards and regulatory guidelines to ensure the production of high-quality pharmaceutical products.

Distribution Reach

With its extensive distribution network, Lupin aims to make doxycycline for injection USP accessible to healthcare providers and patients across various regions.

The company’s robust supply chain capabilities enable efficient distribution to over 100 markets worldwide.

About Lupin Limited

Lupin Limited is an innovation-driven pharmaceutical company with a global footprint.

Headquartered in Mumbai, India, Lupin is renowned for its diverse portfolio comprising branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).

The company’s operations span across key markets in the United States, India, South Africa, Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news